Omadacycline Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

Inclusion Criteria: Experimental: Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb Active Comparator: Healthy Adult Volunteer Exclusion Criteria: Participants in the study or control group will be excluded if any of the following criteria are met: * Less than 18 years of age * History of hypersensitivity to omadacycline or any tetracycline based molecule * History of hypersensitivity to lidocaine or lidocaine derivatives * Pregnant or breastfeeding * Concomitant receipt of any tetracycline based antibiotic therapy * Any other documented reason felt by the investigator to potentially affect the outcomes of the study Additional Exclusion Criteria for Diabetic Patient Study Group: * Participants likely to require multiple surgical interventions during the study period, which therefore could affect placement of the microdialysis catheter Additional Criteria for Healthy Volunteer Control Group: * Body Mass Index (BMI) ≥ 35 kg/m2 * Serum creatinine greater than 1.5 mg/dl or creatinine clearance (CrCl) \< 50ml/min, as calculated by Cockroft-Gault using ideal body weight for all participants * Presence of anemia, thrombocytopenia, or leukopenia as defined by hematocrit, platelet, or white blood cell count \< 75% of the lower limit of normal * Aspartate transaminase, alanine aminotransferase, or alkaline phosphatase greater than five times upper limit of normal * Total bilirubin greater than three times the upper limit of normal * Any known active co-morbidity listed on medical history or that becomes apparent during physical examination * Positive urine drug screen (cocaine, THC, opiates, benzodiazepines, and amphetamines) * History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening. * Use of tobacco- or nicotine-containing products in excess of the equivalence of 5 cigarettes per day. * Consumption of caffeine between Study Days 1 and 4 * Use of prescription or nonprescription drugs, vitamins, or dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, with the exception of acetaminophen at doses of ≤ 1 g/day. The use of hormonal methods of contraception (including oral and transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing IUDs, postcoital contraceptive methods) are permitted.